CBGa is routinely called the mother cannabinoid, and as biochemistry that is accurate. The plant assembles it from a geranyl unit and olivetolic acid, and it is the substrate that THCA synthase, CBDA synthase and CBCA synthase all compete for. Every major cannabinoid in a mature plant passed through it.
Being the starting point is a statement about the plant, not about the bottle on your shelf. In a mature CBD rich hemp plant, CBDA synthase has consumed most of the available CBGa, so what remains at harvest is a small fraction of what was made. Then a second loss: whatever survives decarboxylates to CBG during drying, storage or heated processing. The precursor is squeezed from both ends, so CBGa appears on certificates in small amounts even on products marketed around it.
Decarboxylation also behaves awkwardly here. In the 2016 Mississippi kinetics study, rate constants for THCa were about twice those of CBGa, and CBGa decarboxylation was not straightforward, with an unexplained loss of reactants or products. You cannot calculate a CBG figure from a CBGa figure with any confidence.
CBG’s most striking potency figure is not at a cannabinoid receptor. In a 2010 study using [35S]GTPgammaS binding with mouse brain membranes, CBG behaved as an alpha-2 adrenoceptor agonist with an EC50 of 0.2 nanomolar. The same work had it antagonising 5-HT1A agonist 8-OH-DPAT with an apparent KB of 51.9 nanomolar, acting as a competitive CB1 antagonist at 10 micromolar, and inhibiting evoked mouse vas deferens contractions with an EC50 of 72.8 nanomolar.
The authors flagged a puzzle most summaries drop. CBG showed agonism more potently in the binding assay than in isolated tissue, a gap of more than 300-fold they said should be explained. A sub-nanomolar figure from a membrane preparation describes a receptor, not a dose.
In a 2024 double blind, placebo controlled crossover field trial, 34 healthy adults took 20 mg of hemp derived CBG or placebo a week apart, then the Trier Social Stress Test and a verbal memory test. The result was lower anxiety and stress ratings than placebo, no subjective drug effects and no impairment. It is one single dose study in healthy volunteers, with no clinical population.
The asymmetry is the story. CBG has one small randomised trial, one pilot pharmacokinetic study and a reasonably characterised receptor profile from animal tissue. CBGa has in vitro work, no human trial and no pharmacokinetics. Writing about CBGa as a compound you take runs ahead of the evidence.
The compound that has at least been studied in people is CBG, and the human record is one 34 person single dose trial, so hold it loosely. If you want CBGa, you are choosing a cold processed raw extract and should expect a small certificate number, because the plant used most of it and heat converted the rest.
One practical point is specific to CBG. In the pilot pharmacokinetic study, dietary fat affected CBG blood levels more than the delivery vehicle did, so taking it with food is the best supported variable.
CBG and CBGa containing extracts are novel foods in the UK under Regulation (EU) 2015/2283 as retained in UK law, and being a minor cannabinoid does not take one outside it. The Food Standards Agency keeps a public list of CBD products that may legally be sold while authorisation applications are assessed; a product not on that list, or marked as removed, must be withdrawn.
No health claim for CBD is authorised under Regulation (EC) 1924/2006. That bites hardest here: one published trial recorded lower anxiety ratings that would be easy to turn into a product claim. Reporting what a trial measured is permitted; claiming a supplement will do the same is not.
The FSA advises healthy adults take no more than 10 mg of CBD a day, from a joint position of the Advisory Committee on Novel Foods and Processes and the Committee on Toxicity. It is not recommended for under 18s, anyone on medication or people pregnant or breastfeeding, unless under medical direction.
THC is a controlled drug under the Misuse of Drugs Act 1971, and consumer CBD products must meet the exempt product criteria in the Misuse of Drugs Regulations 2001: no more than 1 mg of a controlled drug per container. The FSA also gives a safe upper intake of 70 micrograms of delta-9 THC a day. A minor cannabinoid product is still a hemp extract and must meet those limits. There is no published intake figure for CBG or CBGa, with no evidence to set one.
Our hemp is grown on our own farm and extracted by us, as it has been since 2010. Every batch certificate reports CBG and CBGa as separate lines alongside CBD, CBDa, THC and THCa, the only way to see how much of each is present rather than implied by a product name.
It measures how much is in the batch, not what either compound does, and in RAW CBD+CBDa Oil 150mg both appear as minor constituents because the plant converted most of the CBGa before harvest. We report the measured number and build nothing on it.
It is the compound CBG comes from, which is not the same thing. CBGa is the acid the plant builds and its synthase enzymes consume, and CBG is what remains after decarboxylation. Only CBG has been given to people in a published trial.
In the one controlled trial, 20 mg produced no subjective drug effects and no measured impairment. The study also recorded lower anxiety and stress ratings than placebo. That is a single dose finding in 34 healthy adults and nothing more.
Because the plant uses it. CBGa is the substrate for the enzymes that make CBDa, THCa and CBCa, so most is converted before harvest, and whatever survives decarboxylates to CBG. Small certificate numbers for CBGa are the norm, not a defect.
The pharmacokinetic evidence points that way. In a pilot crossover study of a single 25 mg oral dose, a high fat meal significantly raised peak plasma concentration, total exposure and terminal half life, and mattered more than the delivery vehicle did.
Cascio MG, Gauson LA, Stevenson LA, Ross RA, Pertwee RG. Evidence that the plant cannabinoid cannabigerol is a highly potent alpha2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist. Br J Pharmacol 2010;159(1):129-141.
Cuttler C, Stueber A, Cooper ZD, Russo E. Acute effects of cannabigerol on anxiety, stress, and mood: a double-blind, placebo-controlled, crossover, field trial. Sci Rep 2024;14(1):16163.
Story G, Lee J, Cohen G, Rani A, Doherty J, Sela DA. Impact of Dietary Fat and Oral Delivery System on Cannabigerol Pharmacokinetics in Adults. Cannabis Cannabinoid Res 2024;9(6):1543-1555.
De Petrocellis L, Ligresti A, Moriello AS, et al. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol 2011;163(7):1479-1494.
van Breemen RB, Muchiri RN, Bates TA, et al. Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants. J Nat Prod 2022;85(1):176-184.
Wang M, Wang YH, Avula B, et al. Decarboxylation Study of Acidic Cannabinoids: A Novel Approach Using Ultra-High-Performance Supercritical Fluid Chromatography/Photodiode Array-Mass Spectrometry. Cannabis Cannabinoid Res 2016;1(1):262-271.
Anderson LL, Low IK, Banister SD, McGregor IS, Arnold JC. Pharmacokinetics of Phytocannabinoid Acids and Anticonvulsant Effect of Cannabidiolic Acid in a Mouse Model of Dravet Syndrome. J Nat Prod 2019;82(11):3047-3055.
Smeriglio A, Giofre SV, Galati EM, et al. Inhibition of aldose reductase activity by Cannabis sativa chemotypes extracts with high content of cannabidiol or cannabigerol. Fitoterapia 2018;127:101-108.
Food Standards Agency. Cannabidiol (CBD) guidance, including the public list of CBD products and the 10 mg a day advice for healthy adults. Updated 28 August 2026.
Last reviewed 6 October 2026.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.